Latest Options News

Loyal Metals Ltd has entered a binding scheme implementation deed with Indonesia’s PT Bumi Resources Tbk to sell all shares for A$0.45 each, valuing the company at approximately A$79.1 million. The transaction offers shareholders an immediate cash premium of over 40% and is supported by Loyal’s board and major shareholders.

Noxopharm’s Sofra™ oligonucleotides, delivered via InhaTarget’s inhalable lipid nanoparticles, achieved a significant reduction in lung inflammation in preclinical models, broadening Sofra’s therapeutic reach and delivery versatility.

Native Mineral Resources (ASX:NMR) reported solid Q3 FY26 gold production from its Charters Towers assets, highlighted by strong mill performance and record pours at Blackjack. The company also secured exclusive mining rights at Podosky, underpinning its regional growth strategy.

Power Minerals has sealed its acquisition of the Morro do Ferro Rare Earths Project, a high-grade rare earth asset in Brazil, setting the stage for accelerated exploration and resource definition.

Dreadnought Resources accelerated progress on gold and critical metals fronts in the March quarter, securing mining approvals, expanding its rare earth portfolio, and delivering high-grade drill results at key prospects.

NEXTDC has launched the retail tranche of its A$1.5 billion fully underwritten entitlement offer at A$12.70 per share, aiming to back accelerated data centre capacity growth amid unprecedented contracted utilisation.

Venari Minerals has delivered a maiden JORC Inferred Mineral Resource Estimate for its Red Mountain Lithium Project in Nevada, revealing 3.03 million tonnes of contained Lithium Carbonate Equivalent. The company also reported improved beneficiation results and completed a share buyback to streamline its register.

Fat Prophets Global Contrarian Fund (ASX: FPC) is raising up to $8.45 million through a pro-rata rights issue priced at a premium, offering one option per new share. The issue is partly underwritten and sees directors committing to full participation.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Katana Capital Limited has declared a fully franked quarterly dividend of 0.5 cents per share for the March 2026 quarter, with the dividend reinvestment plan price set at AUD 1.361271.

Vintage Energy has raised $1.35 million through its recent entitlement offer, issuing over 306 million new shares and attached options. The company is now inviting investors to participate in a shortfall offer as it pushes ahead with operational upgrades and drilling plans.

Investigator Silver has locked in a robust Definitive Feasibility Study for its Paris Silver Project, backed by a strategic A$55 million placement to fast-track early works and financing.